In 2021, the reported number of deaths caused by opioid-related drug poisoning exceeded 81,000. The majority of these fatalities, amounting to over 71,000, were directly linked to fentanyl.1

The standard of care for opioid use disorder (OUD) requires practitioners to offer medication approved by the Food and Drug Administration (FDA) when medically appropriate.2 The FDA has approved three medications for the treatment of OUD: buprenorphine, methadone, and naltrexone.3

The federal government has prioritized increasing the number of practitioners who provide office-based opioid treatment (OBOT) using FDA-approved medications.4 Practitioners authorized to prescribe buprenorphine for OUD have cited the following reasons, among others, for their reluctance to provide OBOT:

  • Inadequate training to support confidence in prescribing;
  • Burdensome regulatory requirements; and
  • Increasing regulatory and law enforcement scrutiny of practitioners who do provide such treatment.5

The Prescriber Safety Initiative responds to these concerns. We equip practitioners to feel confident treating patients with OUD and other medical conditions that require controlled medications.

In addition to providing practitioner-led education on the medical standard of care and best practices, we provide training and technical assistance in regulatory and recordkeeping compliance to prescribers and their staffs so they can withstand increasing scrutiny.

The Prescriber Safety Initiative aims to help professionals be safe and feel safe while prescribing controlled medications.

DEA Announces Removal of Buprenorphine Waiver Requirements
DEA, HHS Extend Telehealth Flexibilities Through 2024
Drug Poisoning Deaths Reach All-Time High
Congress Expands Access To Buprenorphine for OUD
Supreme Court Rules In Favor of Prescribers in Ruan Case
DEA To Expand Surveillance of Prescription Drug Data
COVID-19: DEA, HHS Suspend Telehealth In-Person Exam Requirement
Prescriber Safety Initiative launches
Prescription Opioid Strike Force Expands
DOJ Creates Prescription Opioid Strike Force
DOJ forms Prescription Interdiction and Litigation Task Force
DOJ establishes Opioid Fraud and Abuse Detection Unit
CDC Declares ‘Epidemic of Overdoses’
Buprenorphine is approved by the FDA for OUD treatment
Drug Addiction Treatment Act (DATA 2000, 21 U.S.C. § 823) enacted

*National Center on Health Statistics, CDC Wonder.